Cited by 1,490Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Open access

Herbst, Roy S., Prager, Diane, Hermann, Robert, Fehrenbacher, Lou, Johnson, Bruce E., Sandler, Alan, Kris, Mark G., Tran, Hai T., Klein, Pam, Li, Xin, Ramies, David, Johnson, David H., Miller, Vincent A.·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.02.840

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with non-small-cell lung cancer (NSCLC). Erlotinib was combined with chemotherapy to determine if it could improve the outcome of patients with NSCLC. PATIENTS AND METHODS: TRIBUTE randomly assigned patients with good performance status and previously untreated advanced (stage IIIB/IV) NSCLC to erlotinib 150 mg/d or placebo combined with up to six cycles of carboplatin and paclitaxel, followed by maintenance monotherapy with erlotinib. Random assignment was stratified by stage, weight loss in the previous 6 months, measurable disease, and treatment center. The primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response (OR), and duration of response. RESULTS: There were 1,059 assessable patients (526 erlotinib; 533 placebo). Median survival for patients treated with erlotinib was 10.6 v 10.5 months for placebo (hazard ratio, 0.99; 95% CI, 0.86 to 1.16; P = .95). There was no difference in OR or median TTP. Patients who reported never smoking (72 erlotinib; 44 placebo) experienced improved OS in the erlotinib arm (22.5 v 10.1 months for placebo), though no other prespecified factors showed an advantage in OS with erlotinib. Erlotinib and placebo arms were equivalent in adverse events (except rash and diarrhea). CONCLUSION: Erlotinib with concurrent carboplatin and paclitaxel did not confer a survival advantage over carboplatin and paclitaxel alone in patients with previously untreated advanced NSCLC. Never smokers treated with erlotinib and chemotherapy seemed to experience an improvement in survival and will undergo further investigation in future randomized trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.02.840

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Cancer burden in the year 2000. The global picture
Parkin, D. M., Bray, F. I., & Devesa, S. S. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00267-2 · Cited by 2,169
DECLARATION OF HELSINKI.
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069

Show all 25 references

Sorted by citations

Items 901–1,000 of 1,000

Pharmacogenomics: A reality or still a promise?
BEPLER, G. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.09.014 · Cited by 11
Managing cutaneous side effects of epidermal growth factor receptor (HER1/EGFR) inhibitors
Dick, S. E., & Crawford, G. H. (2005) · Community Oncology · doi:10.1016/s1548-5315(11)70630-1 · Cited by 11
Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
Togashi, Y., Hayashi, H., Nakagawa, K., & Nishio, K. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s50358 · Cited by 11
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.
Karavasilis, V., Kosmidis, P., Syrigos, K. N., Mavropoulou, P., Dimopoulos, M. A., Kotoula, V., Pectasides, D. G., Boukovinas, I., Klouvas, G. D., Kalogera‐Fountzila, A., et al. (2014) · PubMed · Cited by 10
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients
Kumar, R., Lu, S. K., Minchom, A. R., Sharp, A., Davidson, M., Gunapala, R., Yap, T. A., Bhosle, J., Popat, S., & O'Brien, M. E. R. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2950-1 · Cited by 10
Pulmonary Complications of Anticancer Treatment
Sharma, N., Kim, E., & Machtay, M. X. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00058-8 · Cited by 10
A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.
Yagui‐Beltrán, A., & Jablons, D. M. (2009) · PubMed · Cited by 10
Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Males, Smokers, and Non-adenocarcinoma Lung Cancer in Patients with EGFR Mutations
Zeng, Z., Chen, H., Yan, H., Yang, J., Zhang, X., & Wu, Y.-L. L. C. (2013) · The International Journal of Biological Markers · doi:10.5301/jbm.5000039 · Cited by 10
Management of non-small cell lung cancer in the elderly
Froesch, P., Martucci, F., Györik, S., Dutly, A., & Cafarotti, S. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.10.024 · Cited by 10
Efficacy of erlotinib in patients with advanced non-small cell lung cancer
Gao, H., Ding, X., Wei, D., Cheng, P., Su, X., Liu, H., Aziz, F., Wang, D., & Zhang, T. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328349c303 · Cited by 10
A Prospective Crossover Pilot Study to Evaluate the Use of a Topical Wound Gel in Patients with Cutaneous Toxicity Caused by Epidermal Growth Factor Receptor Inhibitors
Wong, S., Lindgren, A., Mummaneni, M., Byun, T., Vasko, C., Arenos, R., Alexson, E., & Osann, K. (2010) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2010.09.003 · Cited by 10
Moving Towards Molecular-Guided Treatments: Erlotinib and Clinical Outcomes in Non-Small-Cell Lung Cancer Patients
Santarpía, M., Pas, T. M. D., Altavilla, G., Spaggiari, L., & Rosell, R. (2013) · Future Oncology · doi:10.2217/fon.13.6 · Cited by 11
Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors
Goel, S., Viteri, S., Morán, T., Coronado, C., Dios, J. L. I., Miguel-Lillo, B., Fernández‐García, E. M., & Rosell, R. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0305-8 · Cited by 10
Targeted drugs for unselected patients with advanced non-small-cell lung cancer: a network meta-analysis.
Sheng, M., Zhao, Y., Wang, F., Li, S., Wang, X., Shou, T., Luo, Y., & Tang, W. (2016) · PubMed · doi:10.3978/j.issn.2072-1439.2016.01.28 · Cited by 10
Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
Zhang, M., Guo, H., Zhao, S., Wang, Y., Yang, M., Yu, J., Yan, Y., & Wang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9503 · Cited by 10
Epidermal Growth Factor Receptor Mutated Advanced Non–Small Cell Lung Cancer
Pakkala, S., & Ramalingam, S. S. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.003 · Cited by 10
Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients
Scodes, S., & Cappuzzo, F. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1746646 · Cited by 10
Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
Shu, Y., Zhang, Q., He, X., & Chen, L. (2021) · Cancer Management and Research · doi:10.2147/cmar.s334643 · Cited by 10
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Maher, A. R., Miake-Lye, I. M., Beroes, J. M., & Shekelle, P. (2012) · Europe PMC (PubMed Central) · Cited by 10
[Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer].
Wang, Y., Wang, L., Liu, Y., Yu, S., Zhang, X., Shi, Y., & Sun, Y. P. (2011) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2011.03.10 · Cited by 10
Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non–Small-Cell Lung Cancer, A Phase II Trial
Cohen, E. E. W., Subramanian, J., Gao, F., Szeto, L. L., Kozloff, M. F., Faoro, L. N., Karrison, T. G., Salgia, R., Govindan, R., & Vokes, E. E. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.10.001 · Cited by 10
Targeted Therapy for the Treatment of Non-Small Cell Lung Cancer: Focus on Inhibition of Epidermal Growth Factor Receptor
Harichand-Herdt, S., & Ramalingam, S. S. (2008) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2008.09.005 · Cited by 10
Bevacizumab in combination with anticancer drugs for previously treated advanced non-small cell lung cancer
Liu, K.-J., Ding, L., & Wu, H. (2015) · Tumor Biology · doi:10.1007/s13277-014-2962-1 · Cited by 10
Non-Small Cell Lung Cancer: New Hope for a Chronic Illness
Tyson, L. B. (2007) · Oncology nursing forum · doi:10.1188/07.onf.963-970 · Cited by 10
Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer
Kim, D. W. N., Nam, T., Choe, K. S., & Choy, H. (2012) · Cancer Research and Treatment · doi:10.4143/crt.2012.44.2.74 · Cited by 10
Optimal Management of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations
Lin, C., & Yang, J. C. (2010) · Drugs · doi:10.2165/11587560-000000000-00000 · Cited by 10
Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions
Chen, H. X., Cleck, J. N., Coelho, R. P., & Dancey, J. E. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.10.002 · Cited by 10
The management of cancer in the elderly: targeted therapies in oncology
Agostara, B., Carruba, G., & Usset, A. (2008) · Immunity & Ageing · doi:10.1186/1742-4933-5-16 · Cited by 10
The clinicopathological and survival differences between never and ever smokers with non-small cell lung cancer.
Muallaoğlu, S., Karadeniz, C., Mertsoylu, H., Beşen, A. A., Sezer, A., Sedef, A. M., Köse, F., & Özyılkan, Ö. (2014) · PubMed · Cited by 10
Pharmacokinetic/Pharmacodynamic Modeling of Schedule-Dependent Interaction between Docetaxel and Cabozantinib in Human Prostate Cancer Xenograft Models
Chen, W., Chen, R., Li, J., Fu, Y., Yang, L., Su, H., Yao, Y., Li, L., Zhou, T., & Lu, W. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.243931 · Cited by 10
EGFR Mutant Lung Cancer
Gong, Y., & Pao, W. J. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_171 · Cited by 10
Novel Therapies Targeting Signaling Pathways in Lung Cancer
Yagui‐Beltrán, A., He, B., Raz, D. J., Kim, J. H., & Jablons, D. M. (2006) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2006.07.001 · Cited by 10
Does Gefitinib Shorten Lung Cancer Survival? Chaos Redux
Keedy, V. L., Arteaga, C. L., & Johnson, D. H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0374 · Cited by 10
An Update on the Role of Epidermal Growth Factor Receptor Inhibitors in Non–Small Cell Lung Cancer
Edelman, M. J. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.10.002 · Cited by 10
Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer
Noda, S., & Kanda, S. (2016) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1164603 · Cited by 10
Regulation of epithelial-mesenchymal transition in retinal pigment epithelium and its associated cellular signaling cascades: an updated review
Gelat, B., Malaviya, P. B., Rathaur, P., Trivedi, K., Chaudhary, P., Patel, B., Johar, K., & Gelat, R. (2023) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-023-00435-z · Cited by 9
Prospective Assessment of Pemetrexed or Pemetrexed Plus Platinum in Combination With Gefitinib or Erlotinib in Patients With Acquired Resistance to Gefitinib or Erlotinib: A Phase II Exploratory and Preliminary Study
Yu, S., Zhang, B., Xiang, C., Shu, Y., Wu, H., Huang, X., Yu, Q., Yin, Y., & Guo, R. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.09.007 · Cited by 9
A Phase II Trial of Erlotinib As Front-Line Treatment in Clinically Selected Patients With Non–Small-Cell Lung Cancer
Pallis, A. G., Voutsina, A., Kentepozidis, N. K., Giassas, S., Papakotoulas, P., Agelaki, S., Tryfonidis, K., Kotsakis, A. P., Vamvakas, L. N., Vardakis, N., et al. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.08.004 · Cited by 9
First-line Systemic Therapy for Metastatic Non-small-cell Lung Cancer – A Review
Chen, Y.-M., Whang‐Peng, J., & Chen, C. (2011) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2011.04.008 · Cited by 9
Clinical and economic review of erlotinib in non-small-cell lung cancer
Yeung, K., & Carlson, J. J. (2012) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.12.42 · Cited by 9
Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts
Cui, J., Zhang, Y., Su, D., Li, T., & Li, Y. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12818 · Cited by 9
The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy
Lee, S. M., Upadhyay, S., Lewanski, C. R., Falk, S. J., Skailes, G., Woll, P. J., Hatton, M. Q. F., Lal, R., Jones, R., Toy, E., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.025 · Cited by 9
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Kunos, C. A., Fabien, J. M., Shanahan, J., Collen, C., Gevaert, T., Poels, K., den Begin, R. V., Engels, B., & Ridder, M. D. (2015) · Journal of Visualized Experiments · doi:10.3791/52875 · Cited by 9
Factors associated with early progression of non‐small‐cell lung cancer treated by epidermal growth factor receptor tyrosine‐kinase inhibitors
Rozensztajn, N., Ruppert, A.-M., Lavolé, A., Leprieur, E. G., Duruisseaux, M., Vieira, T., Rabbe, N., Lacave, R., Antoine, M., Cadranel, J. L., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.180 · Cited by 9
First-Generation Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer: Clinical Impact of the Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization Assay
Hirsch, F. R., Dziadziuszko, R., Varella‐Garcia, M., Franklin, W. A., Gandara, D. R., & Bunn, P. A. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318174e922 · Cited by 9
Predictive Factors for Response and for Resistance to Tyrosine Kinase Inhibitor Therapy in Lung Cancer
Cappuzzo, F. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000268634.17956.5e · Cited by 9
Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Zhang, X., Qin, Y., Li, H., Bai, C., Zhu, T., Xu, J., Wu, C., Wu, M., Wang, C., Song, H., et al. (2011) · PubMed · Cited by 9
Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer
Batus, M., Fidler, M. J., & Bonomi, P. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.104 · Cited by 9
Interstitial lung disease associated to erlotinib treatment: a case report
Castillo, Y. D. C. M., Espinosa, P., Bodí, F., Alcega, R., Muñoz, E., Rabassó, C., & Castander, D. (2010) · Cases Journal · doi:10.1186/1757-1626-3-59 · Cited by 9
Nedaplatin or Oxaliplatin Combined with Paclitaxel and Docetaxel as First-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer
Ruan, Z. (2014) · Medical Science Monitor · doi:10.12659/msm.891318 · Cited by 9
Beyond the Tribute Trial: Integrating Her1/Egfr Tyrosine Kinase Inhibitors With Chemotherapy In Advanced Nsclc
Reck, M. (2006) · Future Oncology · doi:10.2217/14796694.2.1.47 · Cited by 9
EGFR Gene Copy Number Gain is Related to High Tumor SUV and Frequent Relapse after Adjuvant Chemotherapy in Resected Lung Adenocarcinoma
Koh, Y., Jang, B. G., Jeon, Y. K., Kim, T. M., Lee, S., Kim, D., Chung, D. H., Kim, Y. T., Kim, Y., & Heo, D. S. (2011) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq248 · Cited by 9
Targeted agents in cancer therapy
Arkenau, H., Carden, C. P., & Bono, J. S. D. (2008) · Medicine · doi:10.1016/j.mpmed.2007.10.007 · Cited by 9
Review Article: Targeted Therapy: Comprehensive Review
Costa, R. L. B. (2009) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909108330026 · Cited by 10
An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer
Scagliotti, G. V. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.16.2855 · Cited by 9
Factors Affecting Efficacy and Safety of Add-On Combination Chemotherapy for Non-Small-Cell Lung Cancer: A Literature-Based Pooled Analysis of Randomized Controlled Trials
Inoue, K., Narukawa, M., & Takeuchi, M. (2012) · Lung · doi:10.1007/s00408-012-9379-7 · Cited by 8
Docetaxel–carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)—Results of the nonrandomised phase II study TaxErb
Fischer, J. R., Griesinger, F., Fink, T., Salm, T., Marseille, A., & Wolf, M. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.08.006 · Cited by 8
HER family inhibitors in pancreatic cancer: current status and future directions
Berz, D., Miner, T. J., McCormack, E. M., & Safran, H. P. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.3.337 · Cited by 8
The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer.
Voon, P. J., Cho, B. C., Yeo, W.-L., & Soo, R. A. (2010) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.02.03.6 · Cited by 8
EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
Stock-Martineau, S., & Shepherd, F. A. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.015 · Cited by 8
Epstein Barr virus–positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo
Zhang, X., Zhang, R., Ren, C., Xu, Y., Wu, S., Meng, C., Pataer, A., Song, X., Zhang, J., Yao, Y., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006156 · Cited by 8
Customised , Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma ( NSCLC ) = العلاج الفردي و المخصص لسرطان الرئة المنتشر من الخلايا غير الصغيرة
Furrukh, M., Al-Moundhri, M. S., Zahid, K. F., Kumar, S., & Burney, I. A. (2013) · Sultan Qaboos University medical journal · doi:10.12816/0003225 · Cited by 8
Impact of Genetic Markers on Treatment of Non-small Cell Lung Cancer
Lamparella, N. E., Barochia, A., & Almokadem, S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-6176-0_6 · Cited by 8
Anti‐angiogenesis drugs in lung cancer
Lee, S. M., Paul, B. A. A. S., & Wakelee, H. A. (2010) · Respirology · doi:10.1111/j.1440-1843.2010.01715.x · Cited by 8
Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents
Desai, A. A., & Stadler, W. M. (2006) · Current Urology Reports · doi:10.1007/s11934-006-0033-x · Cited by 8
Don’t jump to rash conclusions
Bebb, G. D., Boland, W. K., & Melosky, B. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.7.14920 · Cited by 8
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer
Hartmann, J. T., Kollmannsberger, C., Cascorbi, I., Mayer, F., Schittenhelm, M. M., Heeger, S., & Bokemeyer, C. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9856-0 · Cited by 8
Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer
Zimmermann, S., & Peters, S. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9560-6 · Cited by 8
Functional and pathway enrichment analysis for integrated regulatory network of high- and low-metastatic lung cancer
Chen, Q., Jiao, D., Wu, Y.-Q., Wang, L., Hu, H., Song, J., Yan, J., & Wu, L. (2013) · Molecular BioSystems · doi:10.1039/c3mb70288j · Cited by 8
Clinical Applications of Kinase Inhibitors in Solid Tumors
Pao, W. J., & Girard, N. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00082-6 · Cited by 7
Bioterapia: aplicaciones actuales y futuras en oncología
Prat, A., & Baselga, J. (2007) · Medicina Clínica · doi:10.1157/13107796 · Cited by 8
Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
Jian, H., Li, W., Ma, Z., Huang, J., Feng, J., Song, Y., Gao, B., Zhu, H., Tao, M., Bai, C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08399-8 · Cited by 9
Gefitinib with or without Transarterial Infusion Chemotherapy (Cisplatin) for Large Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations
Zhang, Y., Jiang, L., Jiang, S., Xu, Y., Zhou, B., Huang, G., Liu, D.-M., Wang, Y., Fan, W., Li, J., et al. (2019) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2018.12.705 · Cited by 8
A Phase II Trial of Carboplatin and Gemcitabine with Exisulind (IND #65,056) in Patients with Advanced Non-small Cell Lung Cancer: An Eastern Cooperative Oncology Group Study (E1501)
Masters, G. A., Li, S., Dowlati, A., Madajewicz, S., Langer, C. J., Schiller, J. H., & Johnson, D. H. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30380-4 · Cited by 8
Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents
Desai, A. A., & Stadler, W. M. (2005) · Current Oncology Reports · doi:10.1007/s11912-005-0037-6 · Cited by 8
Cell Signaling Modifiers in Prostate Cancer
Chen, F. L., Armstrong, A. J., & George, D. J. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318161d40f · Cited by 8
Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer
Sequist, L. V. D., & Dziadziuszko, R. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30397-x · Cited by 8
Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?
Tsujino, K., Shiraishi, J., Tsuji, T., Kurata, T., Kawaguchi, T., Kubo, A., & Takada, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp588 · Cited by 8
Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase InhibitorsPreprint
Amler, L. C., Goddard, A. D., & Hillan, K. J. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.048 · Cited by 8
Hepatic failure and hepatorenal syndrome secondary to erlotinib. Safety reminder.
Saif, M. W. (2008) · PubMed · Cited by 8
Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997–2026)
Xie, Z., Chen, X., Gao, R., Yang, M., Han, X., Sun, Y., & Shi, Y. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004016 · Cited by 8
Erlotinib in patients with advanced lung squamous cell carcinoma
Chiang, C., Tsai, C., Chou, T., Chen, Y., Lai, S., Shih, J.-F., Chiu, C., & Lee, Y. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1997-5 · Cited by 8
EGFR Inhibitors as the First-Line Systemic Treatment for Advanced Non-Small-Cell Lung Cancer
Kao, H., Lin, C., & Yang, J. C. (2013) · Future Oncology · doi:10.2217/fon.13.56 · Cited by 7
Multimodality Approach to Management of Stage III Non–Small Cell Lung Cancer
Scarpaci, A., Mitra, P., Jarrar, D., & Masters, G. A. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2012.12.014 · Cited by 7
Toxicity of targeted therapies in elderly patients
Barni, S., Cabiddu, M., & Petrelli, F. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.12.1965 · Cited by 7
Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
Yan, H., Li, Q., Wang, W., Zhen, H., & Cao, B. (2015) · Scientific Reports · doi:10.1038/srep15355 · Cited by 7
Meta-Analysis to Assess the Efficacy and Toxicity of Docetaxel-Based Doublet Compared with Docetaxel Alone for Patients with Advanced NSCLC who Failed First-Line Treatment
Jin, Y., Sun, Y., Shi, X., Zhao, J., Shi, L., Hong, W., & Yu, X. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.015 · Cited by 7
Treatment Outcomes in Elderly with Advanced-Stage Non-small Cell Lung Cancer
Tam, T. C., Ho, J., Wong, M. K.-Y., Wong, W.-M., Wang, J. K.-L., Lam, J. C. M., Lui, M. M., Lam, W. K., Ip, M., & Lam, D. C.-L. (2013) · Lung · doi:10.1007/s00408-013-9498-9 · Cited by 7
Phase IIA Trial Testing Erlotinib as an Intervention against Intraductal Pancreatic Mucinous Neoplasms
Lipkin, S. M., Lee, J., Imagawa, D. K., Hewitt, S. M., Tucker, C., Zell, J. A., Wong, V., García, A., Gonzalez, R. I., Della’Zanna, G., et al. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0373 · Cited by 7
Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation
Mok, T. S. K., D’Arcangelo, M., & Califano, R. (2012) · Drugs · doi:10.2165/1163014-s0-000000000-00000 · Cited by 8
Targeted Therapy and New Anticancer Drugs in Advanced Disease
Silva, S., & Danson, S. J. (2013) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2013.05.008 · Cited by 7
Extending Outcomes: Epidermal Growth Factor Receptor–Targeted Monoclonal Antibodies in Non–Small-Cell Lung Cancer
Joy, A. A., & Butts, C. A. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.s.004 · Cited by 7
Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC
Gao, Z., Han, B., Wang, H., Shi, C., Xiong, L., & Gu, A. (2012) · Oncology Letters · doi:10.3892/ol.2012.631 · Cited by 7
The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer
Zhang, J.-W., Zhao, Y., Guo, Y. Q., Xue, C., Hu, Z.-H., Huang, Y., Zhao, H.-Y., Zhang, J., Wu, X., Fang, W., et al. (2013) · 癌症：英文版 · doi:10.5732/cjc.012.10274 · Cited by 7
Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer
Okuda, K., Hirose, T., Ishida, H., Kusumoto, S., Sugiyama, T., Ando, K., Shirai, T., Ohnishi, T., Horichi, N., Ohmori, T., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0540-6 · Cited by 7
Drug–diagnostic co-development: challenges and issues
Shimazawa, R., & Ikeda, M. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1132163 · Cited by 7
A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer
Altiok (2009) · International Journal of Oncology · doi:10.3892/ijo_00000471 · Cited by 12
New and potential clinical applications ofKRASas a cancer biomarker
Kriegshäuser, G., Auner, V., & Zeillinger, R. (2010) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2010.510512 · Cited by 7
Cancer drug resistance
Karavasilis, V., Reid, A. H. M., Sinha, R., & Bono, J. S. D. (2008) · Elsevier eBooks · doi:10.1016/b978-012369448-5.50020-3 · Cited by 7
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.05.01 · Cited by 716

Authors: Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., Ramies, D., Johnson, D. H., & Miller, V. A.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
ORCID: Herbst, Roy S.
Johnson, Bruce E.
Sandler, Alan
Kris, Mark G.
Tran, Hai T.
Li, Xin
Ramies, David
Johnson, David H.
Miller, Vincent A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-09-01
Volume: 23
Issue: 25
Pages: 5892-5899
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.02.840
OpenAlex: W2162724777
Cited by: 1,490
References: 25
Citations by year: 2026: 9 · 2025: 4 · 2024: 7 · 2023: 11 · 2022: 19 · 2021: 24 · 2020: 29 · 2019: 22 · 2018: 32 · 2017: 48 · 2016: 56 · 2015: 83 · 2014: 79 · 2013: 122 · 2012: 96
FWCI: 123.05
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: erlotinib, carboplatin, paclitaxel, non-small cell lung cancer, EGFR tyrosine kinase inhibitors, combination chemotherapy, never smokers, overall survival, time to progression, objective response, maintenance therapy
MeSH terms: Erlotinib Hydrochloride, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Placebos, Quinazolines, Survival Analysis, Carboplatin, Paclitaxel, Disease Progression, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks